lidocaine has been researched along with Cerebral Ischemia in 49 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Excerpt | Relevance | Reference |
---|---|---|
" To quantify effects of a loading dose of midazolam and lidocaine on the EEG frequency spectrum of full-term neonates with perinatal arterial ischemic stroke (PAIS), 11 full-term infants underwent multi-channel amplitude-integrated EEG (aEEG) and EEG recordings." | 7.78 | Effects of midazolam and lidocaine on spectral properties of the EEG in full-term neonates with stroke. ( Andriessen, P; Dankers, F; de Vries, L; Janssen, F; Jennekens, W; Niemarkt, H; Toet, M; van der Aa, N; van Pul, C, 2012) |
"To study the protective effects of lidocaine and nerve growth factor (NGF) pretreatment on cerebral ischemia/reperfusion (I/R) injury." | 7.76 | [A study of the protective effects of lidocaine and nerve growth factor pretreatment on cerebral ischemia/reperfusion injury in gerbils]. ( Wang, DF; Xie, JD, 2010) |
"The authors' previous study demonstrated that a clinical antiarrhythmic dose of lidocaine, when given before ischemia, is neuroprotective in a rat model of transient focal cerebral ischemia." | 7.71 | Effects of delayed administration of low-dose lidocaine on transient focal cerebral ischemia in rats. ( Capuano-Waters, C; Cottrell, JE; Kass, IS; Lei, B; Popp, S, 2002) |
"We examined the effect of subarachnoid administration of lidocaine on delayed neuronal damage due to forebrain ischemia in rats." | 7.69 | [Subarachnoid administration of lidocaine reduces delayed neuronal damage due to forebrain ischemia in rats]. ( Mizunuma, T; Ohta, S; Suzuki, M, 1996) |
"Dogs were treated with repeated doses of lidocaine or equivalent volumes of saline during hyperbaric therapy after internal carotid air embolism and transient hypertension." | 7.68 | Effect of lidocaine on somatosensory evoked response and cerebral blood flow after canine cerebral air embolism. ( Clark, JB; Dutka, AJ; Hallenbeck, JM; McDermott, J; Mink, R, 1992) |
"We examined the effect of lidocaine on ischemic neuronal injury in the rat forebrain ischemia model." | 7.67 | Effect of lidocaine on forebrain ischemia in rats. ( Louw, D; Ong, BY; Sima, AA; Sutherland, G, 1989) |
"Pretreatment with lidocaine also greatly attenuated the acute hypertension and the increase in intracranial pressure following air embolism." | 5.27 | Protective effect of lidocaine in acute cerebral ischemia induced by air embolism. ( Bradley, ME; Evans, DE; Kobrine, AI; LeGrys, DC, 1984) |
"Cerebral ischemia was induced in dogs on cardiopulmonary bypass circulation by stopping the pump." | 5.26 | Increase in extracellular potassium in the brain during circulatory arrest: effects of hypothermia, lidocaine, and thiopental. ( Astrup, J; Gjerris, F; Skovsted, P; Sørensen, HR, 1981) |
" To quantify effects of a loading dose of midazolam and lidocaine on the EEG frequency spectrum of full-term neonates with perinatal arterial ischemic stroke (PAIS), 11 full-term infants underwent multi-channel amplitude-integrated EEG (aEEG) and EEG recordings." | 3.78 | Effects of midazolam and lidocaine on spectral properties of the EEG in full-term neonates with stroke. ( Andriessen, P; Dankers, F; de Vries, L; Janssen, F; Jennekens, W; Niemarkt, H; Toet, M; van der Aa, N; van Pul, C, 2012) |
"To study the protective effects of lidocaine and nerve growth factor (NGF) pretreatment on cerebral ischemia/reperfusion (I/R) injury." | 3.76 | [A study of the protective effects of lidocaine and nerve growth factor pretreatment on cerebral ischemia/reperfusion injury in gerbils]. ( Wang, DF; Xie, JD, 2010) |
"The authors' previous study demonstrated that a clinical antiarrhythmic dose of lidocaine, when given before ischemia, is neuroprotective in a rat model of transient focal cerebral ischemia." | 3.71 | Effects of delayed administration of low-dose lidocaine on transient focal cerebral ischemia in rats. ( Capuano-Waters, C; Cottrell, JE; Kass, IS; Lei, B; Popp, S, 2002) |
" To examine the mechanisms underlying these seizures, we determined the impact of prior forebrain ischemia on the seizure thresholds of four convulsants with differing modes of action: lidocaine, pentylenetetrazol (PTZ), N-methyl-D-aspartate (NMDA), and picrotoxin." | 3.70 | Forebrain ischemia: effect on pharmacologically induced seizure thresholds in the rat. ( Kim, DC; Todd, MM, 1999) |
" Transient forebrain ischemia produced significant increase in aspartate, glutamate, glycine and taurine (760%, 1070%, 190% and 1210%, respectively), and neuronal blockade by perfusion with a lidocaine (4 mM)-containing medium resulted in 67%, 79%, 58% and 59% reduction in the peak values of each amino acid, respectively." | 3.69 | Lidocaine protects hippocampal neurons against ischemic damage by preventing increase of extracellular excitatory amino acids: a microdialysis study in Mongolian gerbils. ( Adachi, N; Arai, T; Fujitani, T; Kataoka, K; Liu, K; Miyazaki, H; Nakamura, Y, 1994) |
" lidocaine in facilitating recovery from cerebral ischemia was related to an effect on ischemic depolarization, we recorded cortical DC potential, electrocorticogram (ECoG) or EEG, and evoked potentials in rabbits subjected to either 3 or 5 min of complete ischemia." | 3.69 | Lidocaine delays cortical ischemic depolarization: relationship to electrophysiologic recovery and neuropathology. ( Ayad, M; Rubinstein, EH; Verity, MA, 1994) |
"We examined the effect of subarachnoid administration of lidocaine on delayed neuronal damage due to forebrain ischemia in rats." | 3.69 | [Subarachnoid administration of lidocaine reduces delayed neuronal damage due to forebrain ischemia in rats]. ( Mizunuma, T; Ohta, S; Suzuki, M, 1996) |
"The changes in the direct-current potential shift in the hippocampal CA1 area produced by transient forebrain ischemia for 4 min were compared in animals given lidocaine (0." | 3.69 | Lidocaine suppresses the anoxic depolarization and reduces the increase in the intracellular Ca2+ concentration in gerbil hippocampal neurons. ( Adachi, N; Arai, T; Kataoka, K; Liu, K; Yanase, H, 1997) |
"Dogs were treated with repeated doses of lidocaine or equivalent volumes of saline during hyperbaric therapy after internal carotid air embolism and transient hypertension." | 3.68 | Effect of lidocaine on somatosensory evoked response and cerebral blood flow after canine cerebral air embolism. ( Clark, JB; Dutka, AJ; Hallenbeck, JM; McDermott, J; Mink, R, 1992) |
"We examined the effect of lidocaine on ischemic neuronal injury in the rat forebrain ischemia model." | 3.67 | Effect of lidocaine on forebrain ischemia in rats. ( Louw, D; Ong, BY; Sima, AA; Sutherland, G, 1989) |
"In patients with severe head trauma, endotracheal suctioning can result in adverse reactions including cough, systemic hypertension, increased intracranial pressure, and reduced cerebral perfusion pressure." | 1.35 | Endotracheal lidocaine in preventing endotracheal suctioning-induced changes in cerebral hemodynamics in patients with severe head trauma. ( Bilotta, F; Branca, G; Cuzzone, V; Doronzio, A; Lam, A; Rosa, G, 2008) |
"Following middle cerebral artery occlusion, rats received intensive enriched-rehabilitation (ER) of the impaired forelimb for 4 weeks." | 1.33 | Bi-hemispheric contribution to functional motor recovery of the affected forelimb following focal ischemic brain injury in rats. ( Biernaskie, J; Corbett, D; Szymanska, A; Windle, V, 2005) |
"Surgical preparation of focal cerebral ischemia models may alter leukocyte reactivity and thereby make interpretation of leukocyte function following ischemia/reperfusion difficult." | 1.29 | Polymorphonuclear leukocyte behavior in a nonhuman primate focal ischemia model. ( Copeland, BR; del Zoppo, GJ; Ember, JA; Hugli, TE; Mori, E; Thomas, WS, 1994) |
"In complete global ischemia (cardiac arrest) reperfusion is characterized by an immediate reactive hyperemia followed within 20-30 min by a delayed hypoperfusion state." | 1.29 | [Cerebral protection]. ( Cattaneo, AD, 1993) |
"The effects on the pressor response to cerebral ischemia (CIR) of superfusion of the ventral medullary surface with artificial cerebrospinal fluid (CSF) containing local anesthetic was investigated in 10 sinoaortic-denervated, anesthetized cats." | 1.27 | Mediation of pressor responses to cerebral ischemia by superficial ventral medullary areas. ( Polosa, C; Rohlicek, CV, 1983) |
"Pretreatment with lidocaine also greatly attenuated the acute hypertension and the increase in intracranial pressure following air embolism." | 1.27 | Protective effect of lidocaine in acute cerebral ischemia induced by air embolism. ( Bradley, ME; Evans, DE; Kobrine, AI; LeGrys, DC, 1984) |
"Cerebral ischemia was induced in dogs on cardiopulmonary bypass circulation by stopping the pump." | 1.26 | Increase in extracellular potassium in the brain during circulatory arrest: effects of hypothermia, lidocaine, and thiopental. ( Astrup, J; Gjerris, F; Skovsted, P; Sørensen, HR, 1981) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 18 (36.73) | 18.7374 |
1990's | 17 (34.69) | 18.2507 |
2000's | 9 (18.37) | 29.6817 |
2010's | 5 (10.20) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Wright, JL | 1 |
Durieux, ME | 1 |
Groves, DS | 1 |
Mitchell, SJ | 1 |
Merry, AF | 1 |
Armogida, M | 1 |
Giustizieri, M | 1 |
Zona, C | 1 |
Piccirilli, S | 1 |
Nisticò, R | 1 |
Mercuri, NB | 1 |
Xie, JD | 1 |
Wang, DF | 1 |
Cao, H | 1 |
Li, J | 3 |
Wang, J | 1 |
Duan, SM | 1 |
Zeng, YM | 1 |
Melinek, J | 1 |
Hart, AP | 1 |
Wix-Ramos, R | 1 |
Eblen-Zajjur, A | 1 |
Jennekens, W | 1 |
Dankers, F | 1 |
Janssen, F | 1 |
Toet, M | 1 |
van der Aa, N | 1 |
Niemarkt, H | 1 |
van Pul, C | 1 |
de Vries, L | 1 |
Andriessen, P | 1 |
Lei, B | 2 |
Popp, S | 1 |
Capuano-Waters, C | 1 |
Cottrell, JE | 2 |
Kass, IS | 2 |
Lim, YJ | 1 |
Huang, Y | 1 |
Fang, H | 1 |
Zuo, Z | 1 |
WAHAL, PK | 1 |
MATHUR, KS | 1 |
Biernaskie, J | 1 |
Szymanska, A | 1 |
Windle, V | 1 |
Corbett, D | 1 |
Seyfried, FJ | 1 |
Adachi, N | 3 |
Arai, T | 4 |
Bilotta, F | 1 |
Branca, G | 1 |
Lam, A | 1 |
Cuzzone, V | 1 |
Doronzio, A | 1 |
Rosa, G | 1 |
Astrup, J | 4 |
Fitch, W | 1 |
Gelb, AW | 3 |
Rohlicek, CV | 1 |
Polosa, C | 1 |
Evans, DE | 3 |
Kobrine, AI | 3 |
LeGrys, DC | 1 |
Bradley, ME | 1 |
Sørensen, HR | 3 |
Skovsted, P | 1 |
Gjerris, F | 1 |
Sørensen, PM | 1 |
Fujitani, T | 1 |
Miyazaki, H | 1 |
Liu, K | 2 |
Nakamura, Y | 1 |
Kataoka, K | 2 |
Weber, ML | 1 |
Taylor, CP | 1 |
Ember, JA | 1 |
del Zoppo, GJ | 1 |
Mori, E | 1 |
Thomas, WS | 1 |
Copeland, BR | 1 |
Hugli, TE | 1 |
Ayad, M | 1 |
Verity, MA | 1 |
Rubinstein, EH | 1 |
Cattaneo, AD | 1 |
Mizunuma, T | 1 |
Ohta, S | 1 |
Suzuki, M | 1 |
Yanase, H | 1 |
Yamauchi, Y | 1 |
Kotani, J | 1 |
Ueda, Y | 1 |
Wang, D | 2 |
Wu, X | 2 |
Zhong, Y | 1 |
Zhou, Y | 2 |
Shan, G | 2 |
Hu, X | 2 |
Liu, Y | 2 |
Qin, X | 2 |
Xia, Z | 2 |
Kim, DC | 1 |
Todd, MM | 1 |
Wang, G | 1 |
Dutka, AJ | 1 |
Mink, R | 1 |
McDermott, J | 1 |
Clark, JB | 1 |
Hallenbeck, JM | 1 |
Koegler, SM | 1 |
Seidler, FJ | 1 |
Spencer, JR | 1 |
Slotkin, TA | 1 |
Artru, F | 1 |
Terrier, A | 1 |
Tixier, S | 1 |
Jourdan, C | 1 |
Deleuze, R | 1 |
Gao, CR | 1 |
Shokunbi, MT | 1 |
Wu, XM | 1 |
Miller, DJ | 1 |
Ahlemeyer, B | 1 |
Krieglstein, J | 1 |
Prabhakar, NR | 1 |
Mitra, J | 1 |
Van de Graaff, W | 1 |
Haxhiu, MA | 1 |
Cherniack, NS | 1 |
Catron, PW | 1 |
McDermott, JJ | 1 |
Thomas, LB | 1 |
Flynn, ET | 1 |
Sutherland, G | 1 |
Ong, BY | 1 |
Louw, D | 1 |
Sima, AA | 1 |
Ma, SS | 1 |
Steinberg, GK | 1 |
Lam, AM | 1 |
Manninen, PH | 1 |
Peerless, SJ | 1 |
Rassi-Neto, A | 1 |
Warner, DS | 1 |
Godersky, JC | 1 |
Smith, ML | 1 |
Heuser, D | 1 |
Guggenberger, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effectiveness of Add-on Inhibitory Repetitive Transcranial Magnetic Stimulation Over the Contralesional Primary Motor Cortex in Subacute Stroke Patients With Severe Upper Limb Motor Impairment[NCT05505201] | 24 participants (Anticipated) | Interventional | 2022-11-11 | Recruiting | |||
The Effect of Retrobulbar Block on Bi-Hemispheric Cerebral Oxygen Saturation and Early Period Postoperative Cognitive Functions With Lidocaine and Levobupivacaine in Elderly Patients With Ophthalmic Surgery[NCT03189329] | Phase 4 | 66 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
6 reviews available for lidocaine and Cerebral Ischemia
Article | Year |
---|---|
A brief review of innovative uses for local anesthetics.
Topics: Anesthetics, Local; Animals; Brain Ischemia; Decompression Sickness; Dose-Response Relationship, Dru | 2008 |
Lignocaine: neuro-protective or wishful thinking?
Topics: Anesthetics, Local; Anti-Arrhythmia Agents; Brain Ischemia; Cardiopulmonary Bypass; Evidence-Based M | 2009 |
Energy-requiring cell functions in the ischemic brain. Their critical supply and possible inhibition in protective therapy.
Topics: Animals; Barbiturates; Brain; Brain Ischemia; Cell Membrane Permeability; Cerebral Infarction; Cereb | 1982 |
Physiology of the cerebral circulation and current thoughts on the protection of the brain against ischemia.
Topics: Animals; Barbiturates; Blood Pressure; Brain Ischemia; Carotid Artery Diseases; Carotid Artery, Inte | 1984 |
[Brain resuscitation].
Topics: Barbital; Brain; Brain Ischemia; Excitatory Amino Acid Antagonists; Humans; Hypothermia, Induced; Li | 1996 |
Ionic changes in brain ischaemia and alterations produced by drugs.
Topics: Animals; Biological Transport, Active; Brain Ischemia; Calcium; Calcium Channel Blockers; Cats; Extr | 1985 |
43 other studies available for lidocaine and Cerebral Ischemia
Article | Year |
---|---|
N-ethyl lidocaine (QX-314) protects striatal neurons against ischemia: an in vitro electrophysiological study.
Topics: Animals; Brain Ischemia; Cell Hypoxia; Cerebral Cortex; Dose-Response Relationship, Drug; Glucose; I | 2010 |
[A study of the protective effects of lidocaine and nerve growth factor pretreatment on cerebral ischemia/reperfusion injury in gerbils].
Topics: Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Gerbillinae; Ischemic Preconditioning; L | 2010 |
[Effects of lidocaine and thiopental on the neuronal injury in rat hippocampus slice cultures].
Topics: Animals; Brain Ischemia; CA1 Region, Hippocampal; In Vitro Techniques; Lidocaine; Neurons; Rats; Thi | 2003 |
Vertebral artery dissection complicating occipital injection of heparin for treatment of thoracic outlet syndrome.
Topics: Adult; Anesthetics, Local; Anticoagulants; Brain; Brain Ischemia; Female; Forensic Pathology; Heart | 2012 |
Time course of acute neuroprotective effects of lidocaine evaluated by brain impedanciometry in the global ischemia model.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Disease Models, Animal; Electric Impedance; Lidocaine; | 2011 |
Effects of midazolam and lidocaine on spectral properties of the EEG in full-term neonates with stroke.
Topics: Anticonvulsants; Brain Ischemia; Data Interpretation, Statistical; Electroencephalography; Epilepsy; | 2012 |
Effects of delayed administration of low-dose lidocaine on transient focal cerebral ischemia in rats.
Topics: Animals; Anti-Arrhythmia Agents; Brain Ischemia; Cerebrovascular Circulation; Dose-Response Relation | 2002 |
Effects of local and intravenous anesthetics on the activity of glutamate transporter type 2.
Topics: Anesthetics, Intravenous; Anesthetics, Local; Animals; Brain Ischemia; Bupivacaine; Cell Membrane; E | 2003 |
IMMEDIATE TREATMENT OF OCCLUSIVE CEREBROVASCULAR DISEASE--A COMPARATIVE EVALUATION OF DIFFERENT REGIMES OF TREATMENT.
Topics: Adrenocorticotropic Hormone; Anesthesia; Anesthesia, Conduction; Anesthesia, Spinal; Anticoagulants; | 1963 |
Bi-hemispheric contribution to functional motor recovery of the affected forelimb following focal ischemic brain injury in rats.
Topics: Animals; Behavior, Animal; Brain Infarction; Brain Ischemia; Forelimb; Functional Laterality; Infarc | 2005 |
Suppression of energy requirement by lidocaine in the ischemic mouse brain.
Topics: Acidosis; Acidosis, Lactic; Adenosine Diphosphate; Adenosine Triphosphate; Anaerobiosis; Anesthetics | 2005 |
Endotracheal lidocaine in preventing endotracheal suctioning-induced changes in cerebral hemodynamics in patients with severe head trauma.
Topics: Adult; Brain Ischemia; Cerebrovascular Circulation; Craniocerebral Trauma; Female; Glasgow Coma Scal | 2008 |
Anesthetic considerations for carotid endarterectomy.
Topics: Aged; Anesthesia, General; Anesthesia, Inhalation; Blood Pressure; Brain; Brain Ischemia; Carbon Dio | 1984 |
Mediation of pressor responses to cerebral ischemia by superficial ventral medullary areas.
Topics: Animals; Aorta; Blood Pressure; Brain Ischemia; Carotid Arteries; Carotid Sinus; Cats; Cerebrovascul | 1983 |
Protective effect of lidocaine in acute cerebral ischemia induced by air embolism.
Topics: Acute Disease; Animals; Brain; Brain Ischemia; Cats; Embolism, Air; Evoked Potentials, Somatosensory | 1984 |
Inhibition of cerebral metabolism by lidocaine.
Topics: Animals; Brain; Brain Ischemia; Cell Membrane Permeability; Dogs; Electroencephalography; Glucose; L | 1981 |
Increase in extracellular potassium in the brain during circulatory arrest: effects of hypothermia, lidocaine, and thiopental.
Topics: Animals; Brain; Brain Ischemia; Cardiopulmonary Bypass; Cell Membrane Permeability; Dogs; Hypothermi | 1981 |
Inhibition of cerebral oxygen and glucose consumption in the dog by hypothermia, pentobarbital, and lidocaine.
Topics: Animals; Brain Ischemia; Cardiopulmonary Bypass; Dogs; Glucose; Hypothermia, Induced; Lidocaine; Oxy | 1981 |
Lidocaine protects hippocampal neurons against ischemic damage by preventing increase of extracellular excitatory amino acids: a microdialysis study in Mongolian gerbils.
Topics: Animals; Brain Ischemia; Excitatory Amino Acids; Gerbillinae; Hippocampus; Lidocaine; Male; Microdia | 1994 |
Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials.
Topics: Action Potentials; Animals; Brain Ischemia; Evoked Potentials; Hippocampus; Hypoxia, Brain; In Vitro | 1994 |
Polymorphonuclear leukocyte behavior in a nonhuman primate focal ischemia model.
Topics: Animals; Brain Ischemia; Chemotaxis, Leukocyte; Complement C5a; Dose-Response Relationship, Drug; Le | 1994 |
Lidocaine delays cortical ischemic depolarization: relationship to electrophysiologic recovery and neuropathology.
Topics: Animals; Brain; Brain Ischemia; Cerebral Cortex; Electrophysiology; Lidocaine; Male; Rabbits | 1994 |
[Cerebral protection].
Topics: Adrenal Cortex Hormones; Anesthetics; Barbiturates; Benzodiazepines; Brain Ischemia; Calcium Channel | 1993 |
[Subarachnoid administration of lidocaine reduces delayed neuronal damage due to forebrain ischemia in rats].
Topics: Anesthetics, Local; Animals; Brain Ischemia; Cell Death; Lidocaine; Male; Neurons; Prosencephalon; R | 1996 |
Lidocaine suppresses the anoxic depolarization and reduces the increase in the intracellular Ca2+ concentration in gerbil hippocampal neurons.
Topics: Anesthetics, Local; Animals; Brain Ischemia; Calcium; Gerbillinae; Hemodynamics; Ion Transport; Lido | 1997 |
The effects of exogenous epinephrine on a convulsive dose of lidocaine: relationship with cerebral circulation.
Topics: Adrenergic Agonists; Analysis of Variance; Anesthesia, General; Anesthetics, Local; Animals; Blood P | 1998 |
Effect of lidocaine on improving cerebral protection provided by retrograde cerebral perfusion: a neuropathologic study.
Topics: Anesthetics, Local; Animals; Blood Glucose; Blood Pressure; Brain Ischemia; Cardiopulmonary Bypass; | 1999 |
Forebrain ischemia: effect on pharmacologically induced seizure thresholds in the rat.
Topics: Analysis of Variance; Animals; Brain Ischemia; Convulsants; Lidocaine; Male; N-Methylaspartate; Pent | 1999 |
Lidocaine improving the cerebral protection by retrograde cerebral perfusion.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Brain; Brain Ischemia; Cardiopulmonary Bypas | 1998 |
Neuroprotective effect of low-dose lidocaine in a rat model of transient focal cerebral ischemia.
Topics: Anesthetics, Local; Animals; Blood Gas Analysis; Body Weight; Brain Infarction; Brain Ischemia; Hemo | 2001 |
Effect of lidocaine on somatosensory evoked response and cerebral blood flow after canine cerebral air embolism.
Topics: Animals; Blood Pressure; Brain Ischemia; Cerebrovascular Circulation; Disease Models, Animal; Dogs; | 1992 |
Ischemia contributes to adverse effects of cocaine on brain development: suppression of ornithine decarboxylase activity in neonatal rat.
Topics: Animals; Brain; Brain Ischemia; Cocaine; Injections, Intraventricular; Injections, Subcutaneous; Lid | 1991 |
[Use of intravenous lidocaine in neuro-anesthesia and neuro-resuscitation].
Topics: Anesthesia, Intravenous; Brain Ischemia; Humans; Intracranial Pressure; Lidocaine; Neurosurgery; Pse | 1991 |
[Cerebral protection in neurosurgical anesthesia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Brain Ischemia; Brain Neoplasms; Ce | 1991 |
Continuous lidocaine infusion and focal feline cerebral ischemia.
Topics: Animals; Brain Ischemia; Cats; Cerebral Infarction; Cerebrovascular Circulation; Evoked Potentials, | 1990 |
Testing drug effects against hypoxic damage of cultured neurons during long-term recovery.
Topics: Adenosine Triphosphate; Animals; Anticonvulsants; Brain Ischemia; Cell Count; Cell Survival; Cells, | 1989 |
Effect of focal cooling of central chemosensitive areas on cerebral ischemic response.
Topics: Administration, Topical; Anesthesia, Local; Animals; Atropine; Blood Pressure; Brain; Brain Ischemia | 1986 |
Effect of lidocaine after experimental cerebral ischemia induced by air embolism.
Topics: Animals; Blood Pressure; Brain Ischemia; Cats; Embolism, Air; Evoked Potentials, Somatosensory; Fema | 1989 |
Effect of lidocaine on forebrain ischemia in rats.
Topics: Animals; Blood Pressure; Brain; Brain Ischemia; Diencephalon; Lidocaine; Male; Neurons; Rats; Rats, | 1989 |
[Role of lidocaine in protecting central neurons from ischemic or anoxic damage].
Topics: Animals; Brain; Brain Ischemia; Hypoxia, Brain; Lidocaine; Rabbits | 1986 |
The effects of a prophylactic bolus of lidocaine in focal cerebral ischaemia.
Topics: Animals; Brain Ischemia; Cats; Evoked Potentials, Somatosensory; Injections, Intravenous; Lidocaine | 1988 |
Failure of pre-ischemic lidocaine administration to ameliorate global ischemic brain damage in the rat.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Lidocaine; Male; Necrosis; Premedication; Rats | 1988 |
Reduction of experimental intracranial hypertension by lidocaine.
Topics: Acute Disease; Animals; Blood Pressure; Brain Ischemia; Cats; Embolism, Air; Female; Infusions, Intr | 1987 |